SCHEMBL4518802

SCHEMBL4518802

CCc1ccc(C(=O)N(C)C)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 3/20 0.39
PDK2 Q15119 4/20 0.39
PDK4 Q16654 4/20 0.39
PDK1 Q15118 3/20 0.39
PDK3 Q15120 3/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 1/20 0.39
PKM P14618 1/20 0.38
TRPA1 O75762 1/20 0.38
PLK1 P53350 1/20 0.38
MEN1 O00255 2/20 0.38
ABCB1 P08183 1/20 0.38
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
RARB P10826 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4518825 0.82 KMT2A (0.41) ALDH1A1KMT2APDK2PKMMEN1
SCHEMBL14117285 0.82 TRPA1 (0.52) ALDH1A1KMT2APDK2PDK4PDK1
SCHEMBL4508222 0.81 TRPA1 (0.37) ALDH1A1KMT2APDK2PDK4PDK1
SCHEMBL4475121 0.81 PIK3CA (0.41) ALDH1A1KMT2APDK2PDK4PDK1
SCHEMBL4475971 0.81 ALDH1A1 (0.47) ALDH1A1KMT2APDK2PDK4PDK1
SCHEMBL2343149 0.79 ALDH1A1 (0.55) ALDH1A1KMT2ATRPA1PLK1MEN1
SCHEMBL9214669 0.79 ALDH1A1 (0.45) ALDH1A1KMT2APKMTRPA1PLK1
SCHEMBL11806978 0.79 ALDH1A1 (0.45) ALDH1A1PKMTRPA1PLK1TSHR
SCHEMBL4508224 0.79 EED (0.43) ALDH1A1KMT2AHSP90AA1
SCHEMBL4508659 0.78 PPARG (0.48) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 US disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK ALDH1A1 780/4885KMT2A 1713/4885PDK2 210/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK ALDH1A1 780/4885KMT2A 1713/4885PDK2 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.